Funded Startups in Petah Tiqva
Across the 18 Petah Tiqva–listed funding events shown, the largest disclosed round is Pentera’s $60M (Series D, 2025-03-12), which sits far above the rest…
Across the 18 Petah Tiqva–listed funding events shown, the largest disclosed round is Pentera’s $60M (Series D, 2025-03-12), which sits far above the rest of the disclosed amounts—$20M is the next-highest disclosed figure (Ingonyama, Seed, 2023-11-09), with most other reported rounds clustered well below that. The most recent disclosed entry is CanFite BioPharma at $15M (2025-07-28), while the oldest dated row is Pcysys at $25M (2020-09-09), giving a multi-year span from 2020-09-09 through 2025-07-28.
The dataset also shows concentration patterns in both time and classification: 5 of the 18 rows fall between 2024-05-27 and 2025-07-28, and “Series Unknown” appears in 6 of 18 rows. Sector-wise, Biotechnology shows up in multiple entries (CanFite BioPharma 2025-07-28 $15M; PolyPid 2024-08-01 $8M; DreaMed Diabetes 2024-08-19 is labeled AI rather than biotech; Deep Optics is Consumer Electronics; plus Digma Medical 2022-06-07 is Biotechnology), while undisclosed amounts appear in 3 of 18 rows (NitroFix 2025-01-01; Deep Optics 2022-11-08; Digma Medical 2022-06-07).
Most recent rounds
18 shownRelated listings
Frequently asked
What stands out in the size distribution of disclosed rounds in Petah Tiqva?
Pentera’s $60M (Series D, 2025-03-12) is the only disclosed round in the $50M+ range, with the next-highest disclosed amount at $20M (Ingonyama, Seed, 2023-11-09). Reported mid-to-lower disclosed rounds include $25M (Pcysys, 2020-09-09) and multiple $15M rounds (CanFite BioPharma, 2025-07-28 and Yoom, 2022-10-17), but none approach $60M.
Are there notable time clusters within the most recent entries shown?
Yes: 5 of the 18 rows date from 2024-05-27 to 2025-07-28, including Unlimited Robotics ($5M, Seed, 2024-05-27), PolyPid ($8M, 2024-08-01), CanFite BioPharma ($15M, 2025-07-28), and Pentera ($60M, 2025-03-12). Several other recent entries are also early-2025 (NitroFix on 2025-01-01 is undisclosed; Pentera and CanFite follow in 2025).
How much of the list has missing or non-disclosed financing amounts and how does that affect comparisons?
3 of 18 rows are marked “undisclosed” (NitroFix, 2025-01-01; Deep Optics, 2022-11-08; Digma Medical, 2022-06-07), so comparisons based on disclosed dollars rely on the remaining 15 rows. The standout size comparison still holds on disclosed amounts: $60M (Pentera) vs. $20M (Ingonyama) for the next disclosed peak.
Does the stage mix skew toward any particular label, especially around “Series Unknown”?
Stage labels are frequently not specified: “Series Unknown” appears in 6 of 18 rows (e.g., CanFite BioPharma 2025-07-28 $15M; NitroFix 2025-01-01 undisclosed; PolyPid 2024-08-01 $8M; DreaMed Diabetes 2024-08-19 $3M; Airobotics 2024-11-07 $1M; Yoom is explicitly Series A, so not counted here). By contrast, named stages include multiple Seed/Series A/B entries such as Ingonyama Seed $20M (2023-11-09), NsKnox Series B $17M (2023-01-18), and Cogniteam Series A $6M (2022-05-09).
Are there outliers worth separate attention beyond the largest round?
Besides Pentera’s $60M (2025-03-12), there’s a small disclosed outlier at SolidT’s $50K (Series Unknown, 2023-05-23), which is dramatically below the rest of the disclosed amounts. Several entries cluster around $10M–$28M (e.g., Cogniteam $6M is lower; Twine Solutions $28M in 2021-05-19 and Pcysys $25M in 2020-09-09), but SolidT sits near the floor of disclosed figures in this slice.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.